focus -WSS

focus

author：explore 2025-10-01 04:10:51 - browse：19

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

hotspot

WSS

Mayo Clinic plans $5B tech

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Pediatric cancer treatments threatened by a new FDA policy

Study on Amgen’s bispecific immunotherapy produces positive data

Roche acquires Telavant from Roivant, adding experimental IBD treatment

FDA investigates CAR

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Sports medicine is finally prioritizing gender equality

Why a market frenzy over new weight loss drugs defies logic

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: Ending the crisis of Black deaths in the U.S.

Medical leaders decry Supreme Court decision on affirmative action

The EPA's new lead rule: How one expert crunched the numbers

Psychedelics group wrestles with new pharma identity

FDA investigates CAR

focus

Health tech investors get more selective as pandemic boom fades

The problems with dementia villages

STAT Summit: How researchers deal with rejection

How to pay for weight loss drugs and save Medicare

Diagnostic tests are hitting their mathematical limits

Cassava Sciences’ Alzheimer’s clinical trials should be halted

explore

hotspot

hotspot

explore